Raising the bar for lower-risk myelodysplastic syndromes |
Jun 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
Jun 2023 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
Jun 2023 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Jun 2023 |
American Journal of Hematology |
Aplastic Anemia |
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
Jun 2023 |
Leukemia & Lymphoma |
Aplastic Anemia |
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Therapy-related myelodysplastic syndromes in the genomics era |
Jun 2023 |
Bulletin du Cancer |
Myelodysplastic Syndromes (MDS) |
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction |
Jun 2023 |
SAGE Open Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |